Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients we serve. This month we spoke with Nick Theodore, Senior Vice President of Global Sales and Marketing for Nova Biomedical.
Tell us about your organization and your current initiatives.
Nova Biomedical is a technology company based in Waltham, Massachusetts, that provides state-of-the-art, automated cell culture analyzers for the biopharmaceutical market. In 1998, Nova introduced the first line of chemistry analyzers for the biotechnology industry—the BioProfile® series. Nearly a decade later, Nova added the BioProfile Flex series featuring an expanded menu and real-time analysis of key metabolites, nutrients, and gases in cell culture media. In 2011, we announced the BioProfile CDV Automated Cell Density/viability analyzer, which measures up to 80 million cells per mL and provides results in less than three minutes. Our latest analyzer, FLEX2, features no-maintenance chemistry sensors, onboard automated quality control, and small sample volume for automated analysis from microbioreactor systems such as the ambr® 15 cell culture. BioProfile analyzers optimize and enhance process development, reliability, and reproducibility; help improve manufacturing yield and quality; and reduce testing time and cost.
How do your organization’s activities help patients now and into the future?
Our technologies enable companies to bring groundbreaking treatments to market faster, leading to more options for patients and bringing new treatments for diseases sooner. Our technologies enable this by maximizing scientific knowledge of cell culture processes and practices.
What do you see as the biggest challenge facing the life sciences industry today?
Life Sciences is a very dynamic industry and we see speed to market as one of the biggest challenges our customers are facing. The technologies and capabilities have advanced exponentially in the last decade and that has brought fierce competition to the marketplace. That is why the focus now is developing the automation and analytical capabilities in partnership with our customers to allow them greater experimental capabilities which results in much shorter development timelines than have been previously.
What’s next for your organization / what are you focused on in the coming year?
We are focused on enhancing our product portfolio in the area of cell culture automation. We believe this is what will ultimately allow our customers to bring their products to market faster and bring a better quality of life to millions of new patients worldwide.
If you’re interested in being featured in MassBio’s Member Spotlight, please see guidelines here.